His mother's surgery changed everything. Now he's making robotic surgery affordable for 3 billion people.
Saurya Mishra left Philips Healthcare, led R&D at a YC startup, and spent 14 years mastering medical devices — all to build what India's hospitals can't afford to buy from Intuitive Surgical. Articulus Surgical's Pulsar robot is 5x cheaper than a Da Vinci, 90–95% Made in India, and backed by Kalaari Capital. India's surgical robotics revolution starts here.
Saurya Mishra
Founder & CEO · Articulus Surgical
A Surgeon's Family, A Personal Crisis, A Mission
Saurya Mishra grew up in Cuttack, Odisha, in a family of surgeons. He saw healthcare inequality not as a statistic but as daily life — the gap between what a patient in a Delhi private hospital could access and what was available to someone in a government ward in Odisha.
The moment that crystallised everything came when his mother needed a hysterectomy. She underwent open surgery — the standard in most Indian hospitals — and her long recovery interrupted her PhD work. Saurya knew that minimally invasive robotic surgery would have meant a fraction of the recovery time. He knew the technology existed. He knew it was simply unaffordable.
"We aim to make advanced medical technologies, particularly surgical robotics, accessible to everyone, not just the privileged few," he says. It is not a pitch line. It is, quite literally, his mother's story.
14 Years in Medical Devices, Then One Leap
Saurya did not walk straight from university into a startup. He spent over a decade building the specific expertise the problem demanded: R&D at Philips Healthcare India, then heading R&D at Morphle Labs — a YC-funded startup building robotic pathology systems.
At IIT Kharagpur, where he earned his B.Tech and M.Tech in Mechanical Engineering with a focus on robotics and control systems, he had already worked on India's first adult humanoid robot project. He understood, from years of hard experience, that the gap between a prototype and a certified medical device was measured not in months but in years of regulatory rigor.
When he founded Articulus Surgical in 2021, he did so with unusual clarity about the full journey ahead — preclinical trials, CDSCO certification, surgeon training, hospital partnerships, and the patient capital needed for all of it. He built the company to last, not to flip.
Pulsar, Galaxi, Nebula — The Three-Robot Ecosystem
India performs over 10 million minimally invasive abdominal surgeries annually, yet robotic surgery penetration sits below 1%. The reason is simple: a Da Vinci system costs $1–2 million to install, plus high per-procedure consumable fees. Only the top 5% of Indian hospitals can absorb that cost.
Articulus's answer is Pulsar — a compact, on-demand surgical robot designed to be at least 5x more affordable in both capital and operating cost. It is interoperable with existing laparoscopic infrastructure (compatible with 2,500+ hospitals in India without new investment), requires a small footprint, and allows surgeons to switch between manual and robotic mode on-demand. Each robot contains 6–8 custom-built motors that move in precise synchrony, controlled by proprietary software that filters unintended movements in real time at 10,000 readings per second.
Galaxi is the optics companion — an intelligent camera robot for surgical visibility. Nebula is the training simulator, already commercially deployed, ensuring surgeon adoption from day one. Together, the three form a complete, self-contained robotic surgery ecosystem — 90–95% built in India, targeting 5,000 deployments across Tier II and III cities.
"Robot plus surgeon is better than robot alone, and better than surgeon alone. We are not replacing the surgeon. We are making every surgeon's hands more precise."
— Saurya Mishra, Founder & CEO, Articulus Surgical
Company Timeline
- Pre-2021
Saurya Mishra spends 14+ years in medical devices — R&D at Philips Healthcare India, then head of R&D at Morphle Labs (YC-funded robotic pathology). He builds India's first adult humanoid robot project along the way.
- 2021
Articulus Surgical founded in Bengaluru. Early support from Startup India, BIRAC Bio-Innovation Grant, and IIT Delhi's incubator IHFC. Mission: make robotic surgery accessible to the next 3 billion people.
- 2022–23
₹8.8 crore seed funding raised from IHFC, Gaurav Agarwal (Innvolution Healthcare), and Sandeep Daga (Nine Rivers Capital). Three-product ecosystem — Pulsar, Galaxi, Nebula — takes shape. Nebula (training simulator) enters commercial deployment.
- 2023
Featured in Forbes India's emerging startups edition (December 2023). Named CNBC's Top 100 Startups 2024. Saurya awarded Fellowship of the Royal Academy of Engineers, UK — one of the world's most prestigious engineering honours.
- 2024–25
CDSCO test licences secured. Preclinical trials commenced. ISO 13485 certification in progress. Full CDSCO certification targeted for mid-2026. Named NASSCOM Emerge 50 (2025). Customer pre-orders received from Indian hospitals.
- Early 2026
Undisclosed seed round led by Kalaari Capital closed. Capital deployed to accelerate hospital rollout across India, establish dedicated surgeon training centres, and expand into general surgery, gynaecology, urology, GI surgery, and surgical oncology.
Frequently Asked Questions
Who founded Articulus Surgical and what is his background?
Saurya Mishra founded Articulus Surgical in 2021 in Bengaluru. He is an IIT Kharagpur alumnus with B.Tech and M.Tech in Mechanical Engineering (robotics focus). He spent 14+ years in medical devices — R&D at Philips Healthcare India and as head of R&D at Morphle Labs (YC-funded). He is a Fellow of the Royal Academy of Engineers, UK, and is inspired by a personal family experience with surgical inequality.
What makes Pulsar different from Da Vinci or CMR Surgical?
Pulsar is designed to be at least 5x more affordable than existing systems on both Capex (purchase cost) and Opex (per-procedure cost). It is interoperable with existing laparoscopic hospital infrastructure, has a compact footprint for smaller ORs, and offers on-demand switching between manual and robotic modes. Articulus also offers a free-device, pay-per-procedure model for smaller hospitals — removing the upfront cost barrier entirely.
What recognition has Articulus Surgical received?
Articulus has been named in NASSCOM Emerge 50 (2025), CNBC's Top 100 Startups (2024), and Forbes India's emerging startups (December 2023). Founder Saurya Mishra has been awarded a Fellowship from the Royal Academy of Engineers, UK — one of the most prestigious international engineering honours. The company has also been backed by BIRAC's Bio-Innovation Grant and Startup India.
When will Articulus Surgical's Pulsar receive regulatory approval?
Articulus holds CDSCO test licences and full certification is targeted for mid-2026. Preclinical trials are underway. Clinical studies are planned to begin in early 2026. The Nebula simulation and training system is already in commercial deployment. Pulsar has not yet received CDSCO (India) or FDA (US) approval for clinical use on humans.